InVivo Biosystems

About:

InVivo Biosystems is using alternative, non-mammalian model organisms in early biological and biomedical research.

Website: https://invivobiosystems.com//

Twitter/X: invivobiosystem

Top Investors: Oregon Venture Fund, National Institutes of Health, National Human Genome Research Institute, Cascade Seed Fund, Portland Seed Fund

Description:

InVivo Biosystems is using alternative, non-mammalian model organisms in early biological and biomedical research. The company develops solutions and commercializes proprietary systems for the genetic modification of simple microscopic living animals through its transgenic platform to act as human proxies for disease research, drug discovery and help researchers reveal new insights into the true nature of genetic mutations. InVivo Biosystems provides essential services to help pharmaceutical, nutraceutical, biotechnology companies and academic research institutions around the globe accelerate their research and drug development efforts. The company's mission is to enable scientists and researchers around the world to better understand human health and explore potential treatments for high-impact disorders such as Alzheimer’s disease, epilepsy, and cancer by offering a more affordable and accessible platform.

Total Funding Amount:

$12.8M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Eugene, Oregon, United States

Founded Date:

2011-01-01

Contact Email:

support(AT)invivobiosystems.com

Founders:

Janis Weeks, Matt Beaudet

Number of Employees:

11-50

Last Funding Date:

2024-01-03

IPO Status:

Private

Industries:

© 2025 bioDAO.ai